Barnaby Pickering
Senior Writer
Barnaby lives and works in Yorkshire. Having graduated from University College London with a master's degree in biomedical engineering in 2020, Barnaby is passionate about cutting-edge medical technology. Key areas of focus for Barnaby include diabetes, nanotechnology, machine learning and artificial intelligence.
Latest From Barnaby Pickering
Octave Biosciences Takes It Up Another Semitone With Michael J Fox Foundation Grant
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
Digital Health Roundup: Black Friday Hits – Digital Twins, Biowearables, Robotics, Cardiology
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with Abbott’s head of Lingo Biowearables and top executives at Twin Health. Reed Miller provides an update on J&J MedTech’s launch of the Ottava soft-tissue robotic surgery system and Barnaby Pickering talks about his recent interview with Leo Grady, former CEO of Paige AI, to talk about his new start-up Jona.
”Honey, I Shrunk My Hybrid Closed Loop Insulin Delivery System” – ViCentra’s Kaleido Launches
The closed loop system market is getting busier and busier; however ViCentra is hoping that its Kaleido system, one of the smallest pumps available, will be differentiated enough to secure market share.
Podcast: Discussing The Potentials Of And Challenges For Digital Therapeutics
In this podcast, Medtech Insight speaks to Andy Molnar, CEO of the digital therapeutics alliance; Joel Morse, CEO and co-founder of Curavit and Owen McCarthy, CEO and co-founder of MedRhythms. The trio discuss the current situation surrounding digital therapeutics, and where they believe they are headed in the coming years.
Investing In Digital: Slow And Steady May Win This Race
Getting out the gates early is usually the playbook for VC, however when it comes to new technologies with untested commercial pipelines, waiting and seeing may be a smarter approach.